Sample Page
Author:
Dogwood Therapeutics, Inc.
Posted Date:
May 18, 2026
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
Dogwood Therapeutics, Inc.
May 18, 2026
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
Dogwood Therapeutics, Inc.
May 14, 2026
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Dogwood Therapeutics, Inc.
May 7, 2026
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
Dogwood Therapeutics, Inc.
April 23, 2026
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
Dogwood Therapeutics, Inc.
April 15, 2026
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Dogwood Therapeutics, Inc.
March 18, 2026
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
Dogwood Therapeutics, Inc.
February 2, 2026
